{
  "id": "catheter-ablation",
  "title": "Catheter ablation",
  "lang": "en",
  "source_lang": "en",
  "summary": "Catheter ablation treats cardiac arrhythmias by creating targeted lesions that eliminate abnormal electrical activity or interrupt its conduction.",
  "category": "health",
  "subcategory": "medicine",
  "type": "concept",
  "aliases": [
    "Cardiac catheter ablation",
    "cardiac ablation",
    "transcatheter ablation"
  ],
  "generated_at": "2026-11-05",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/catheter-ablation/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/catheter-ablation/",
      "json": "https://aiwiki.page/zh/catheter-ablation.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Catheter ablation is a minimally invasive treatment for cardiac arrhythmias in which thin, flexible instruments are introduced into the heart through blood vessels and used to destroy or electrically isolate small areas of tissue. These areas may generate abnormal impulses, provide an abnormal conduction pathway, or sustain a circulating electrical wave. Most procedures use radiofrequency heating, freezing, or pulsed electric fields to create lesions. Unlike electrical cardioversion, which terminates an arrhythmia at a particular moment, ablation attempts to alter the tissue responsible for its initiation or maintenance.\n\nThe procedure is a central treatment in cardiac electrophysiology. Its purposes range from definitive elimination of certain supraventricular tachycardias to reduction of recurrent atrial fibrillation or ventricular tachycardia. Outcomes depend strongly on the arrhythmia mechanism, the location and extent of abnormal tissue, and accompanying structural heart disease. Some procedures target a few millimetres of tissue; others require extensive mapping and multiple lesions distributed across a cardiac chamber.\n\nCatheter ablation combines intracardiac electrical recording, programmed stimulation, three-dimensional navigation, imaging, and controlled energy delivery. Its development has reduced the need for open-heart arrhythmia operations and long-term drug treatment in several conditions, but it remains an invasive intervention with risks that differ substantially among procedures."
    },
    {
      "heading": "Electrical mechanisms and biological targets",
      "text": "The normal heartbeat begins in the sinoatrial node, spreads through the atria, passes through the atrioventricular node, and reaches the ventricles through the His–Purkinje system. Arrhythmias arise when impulse formation, conduction, or both become abnormal. Ablation targets these abnormalities while attempting to preserve the myocardium and specialized conduction tissue needed for normal cardiac function.\n\nThree broad mechanisms explain many ablation targets. Abnormal automaticity occurs when tissue outside the normal pacemaker generates spontaneous impulses. Triggered activity results from abnormal depolarizations associated with a preceding action potential, often involving disturbed intracellular calcium handling. Re-entry occurs when an electrical wave repeatedly circulates through tissue that has recovered sufficiently to conduct again. A re-entry circuit requires an appropriate combination of conduction pathways, conduction delay, and differences in refractoriness. A lesion placed across a critical part of the circuit can prevent further circulation without removing the entire abnormal region.\n\nIn atrioventricular nodal re-entrant tachycardia, functionally distinct fast and slow conduction pathways in or near the atrioventricular node participate in the circuit. Ablation usually modifies the slow-pathway region rather than destroying the compact node. In Wolff–Parkinson–White syndrome, an accessory atrioventricular pathway can bypass normal nodal conduction and participate in tachycardia. Eliminating conduction through that pathway can remove both the re-entry substrate and, when present, ventricular pre-excitation.\n\nMore extensive arrhythmias require a different anatomical strategy. Typical atrial flutter generally circulates around the tricuspid annulus and depends on conduction through the cavotricuspid isthmus, a region between the tricuspid valve and inferior vena cava. A continuous line of block across this isthmus interrupts the circuit. Scar-related ventricular tachycardia often involves surviving muscle bundles within or around a myocardial scar. These bundles can form slow-conduction channels whose entrances, exits, or central portions become ablation targets.\n\nA lesion must produce durable electrical interruption, not merely a temporary change. Immediately after energy delivery, local tissue swelling, altered excitability, and reversible injury can suppress conduction. Later recovery may reveal a surviving gap. Durable thermal lesions contain irreversible cellular injury and subsequently develop fibrosis; pulsed-field lesions also undergo tissue healing after irreversible cellular damage. Lesion depth, continuity, and position therefore matter as much as whether an arrhythmia stops during the procedure. Termination may identify an important target, but additional testing is often needed to establish that the intended pathway or circuit has actually been interrupted."
    },
    {
      "heading": "Energy sources and lesion formation",
      "text": "Radiofrequency ablation delivers alternating electrical current, typically at frequencies of several hundred kilohertz, through an electrode in contact with cardiac tissue. Resistive heating occurs close to the electrode, while heat conduction extends injury deeper into the myocardium. Sufficient heating produces irreversible protein damage and cell death. Lesion dimensions depend on power, application duration, electrode size, tissue contact, blood flow, and local anatomy. The temperature measured at the electrode is not necessarily the highest temperature within the tissue.\n\nIrrigated catheters circulate saline around the electrode, limiting surface overheating and permitting greater energy delivery. Many systems also measure contact force. Too little contact can produce an ineffective lesion, whereas excessive force can contribute to mechanical injury or overheating. Rapid intramyocardial heating may vaporize water and produce a “steam pop,” sometimes associated with perforation. Excessive surface heating can cause coagulum or char, increasing concern about embolic material. Power, contact force, impedance change, and application time are therefore interpreted together rather than as interchangeable measures of lesion quality.\n\nCryoablation extracts heat through a catheter tip or balloon. Freezing disrupts cellular structures and microcirculation, producing tissue injury after cooling and thawing. A cryocatheter adheres to tissue during freezing, which can improve positional stability. At selected targets near the normal conduction system, controlled initial cooling can permit assessment of an electrical effect before a full lesion is completed. Cryoballoon systems instead create a broad, circumferential lesion around pulmonary vein openings and are principally used for pulmonary vein isolation. Their geometry differs substantially from point-by-point radiofrequency ablation.\n\nPulsed-field ablation applies brief, high-voltage electrical pulses that cause irreversible electroporation: disruption of cell membranes sufficient to kill targeted cells. Its principal mechanism differs from the deliberate heating or freezing used in thermal ablation. Myocardial cells and neighbouring tissues have different electrical susceptibility, creating the possibility of preferential myocardial injury. Clinical systems vary in electrode configuration, waveform, pulse sequence, and catheter shape, so results from one system cannot automatically be generalized to every device using pulsed electric fields.\n\nNo energy source removes all procedural risk. Radiofrequency and cryothermal energy can damage nearby nerves, vessels, or other structures. Pulsed-field ablation has reduced some forms of collateral injury in clinical studies, but vascular complications, perforation, thromboembolism, coronary spasm, and haemolysis remain relevant considerations. Substantial haemolysis can contribute to acute kidney injury. Mechanical catheter manipulation and vascular access introduce risks independently of the energy used. Selection of an energy source therefore reflects both the intended lesion geometry and the surrounding anatomy, rather than a simple ranking from weak to strong or from unsafe to safe."
    },
    {
      "heading": "Mapping, imaging, and procedural workflow",
      "text": "Ablation ordinarily begins with characterization of the rhythm using electrocardiography, ambulatory recordings, and relevant cardiac imaging. The surface electrocardiogram may suggest an accessory pathway location, a typical flutter circuit, or the origin of ventricular ectopy. Ultrasonography, particularly echocardiography, defines chamber size, ventricular function, valve disease, and other structural abnormalities. Magnetic resonance imaging can identify myocardial scar, while computed tomography may delineate pulmonary veins or complex anatomy. Imaging requirements differ by procedure; no single set of tests is necessary for every ablation.\n\nMost catheters enter through femoral veins and are advanced to the right atrium, coronary sinus, or right ventricle. Access to the left atrium generally requires transseptal puncture through the interatrial septum. The left ventricle can be reached through a transseptal route or retrogradely through the arterial circulation and aortic valve. Some ventricular procedures require access to the epicardial surface through a percutaneous pericardial puncture. These routes have different mechanical and thromboembolic risks. Sedation or general anesthesia is selected according to procedural requirements, patient characteristics, and the need to induce or maintain an arrhythmia.\n\nIntracardiac electrodes record local electrograms and deliver pacing stimuli. An electrophysiology study measures conduction intervals, tests pathway properties, and attempts to induce the clinical tachycardia. Activation mapping identifies the sequence of local electrical activation during an arrhythmia. Pace mapping compares the surface electrocardiogram produced by pacing at a candidate site with the recorded clinical rhythm. Entrainment uses pacing slightly faster than a re-entrant tachycardia to examine whether a location belongs to, or is connected with, its circuit.\n\nThree-dimensional electroanatomical mapping systems combine catheter location with electrical measurements to reconstruct a chamber. Voltage maps can identify regions of low-amplitude signals associated with scar, although voltage also depends on electrode configuration, contact, activation direction, and tissue thickness. High-density mapping collects many points rapidly, helping reveal narrow conduction channels and gaps between prior lesions. Intracardiac echocardiography can show catheter position, septal anatomy, and emerging pericardial fluid. These technologies reduce dependence on fluoroscopy, and selected procedures can be performed with little or no fluoroscopic exposure.\n\nAfter energy delivery, operators test a mechanism-specific endpoint. Examples include loss of accessory pathway conduction, bidirectional block across a flutter line, electrical isolation of the pulmonary veins, or failure to re-induce a targeted tachycardia. Waiting periods and pharmacological provocation may expose transient rather than durable block. The procedure concludes with catheter removal, vascular haemostasis, and monitoring for rhythm changes, bleeding, conduction disturbance, and other early complications."
    },
    {
      "heading": "Supraventricular tachycardias and atrioventricular node ablation",
      "text": "Several forms of supraventricular tachycardia are particularly suitable for ablation because their circuits depend on a discrete, anatomically accessible structure. In atrioventricular nodal re-entrant tachycardia, the target is usually the inferior extension of the slow pathway near the coronary sinus opening and tricuspid annulus. This location is separated from the compact atrioventricular node but remains close enough that injury to normal conduction is an important concern. Radiofrequency and cryothermal techniques are both used. Acute success commonly exceeds 95% in experienced centres, although recurrence and complication rates vary with technique and population.\n\nAccessory pathways connect atrial and ventricular myocardium outside the normal atrioventricular conduction system. They can lie along either atrioventricular valve annulus or in septal regions. Mapping seeks the site of earliest ventricular activation during pre-excitation, earliest atrial activation during retrograde pathway conduction, or a discrete accessory pathway potential. Left-sided pathways may be approached transseptally or through the aorta. Septal pathways require particular care because of their proximity to the normal conduction system, while pathways associated with the coronary venous system can present distinct access and coronary artery hazards.\n\nTypical atrial flutter is treated by creating a line across the cavotricuspid isthmus. Its accepted procedural endpoint is bidirectional conduction block, not simply termination of flutter. Conduction around a line, slow conduction through a residual gap, and transient injury can all create misleading appearances of success. Other atrial tachycardias may arise from a focal source or a larger re-entry circuit around scar, valve annuli, or previous surgical incisions. Such arrhythmias require individualized mapping and are not necessarily treated by the standard isthmus line.\n\nFocal atrial tachycardia is often localized by finding the earliest atrial activation relative to the surface P wave. Potential sites include the crista terminalis, valve annuli, coronary sinus region, and pulmonary veins. Ablation becomes more difficult when the focus lies close to the atrioventricular node, a phrenic nerve, or another vulnerable structure. Intermittent arrhythmias may also be difficult to map if they cannot be reproduced during the procedure.\n\nAtrioventricular node or junction ablation has a fundamentally different purpose. It intentionally interrupts conduction from the atria to the ventricles, controlling the ventricular rate in selected patients with otherwise difficult-to-control atrial arrhythmias. It does not eliminate atrial fibrillation itself and does not remove its associated thromboembolic risk. Permanent cardiac pacing is required afterward. The consequences of long-term ventricular pacing, including its interaction with ventricular function, make pacing strategy an integral part of this treatment rather than a separate technical detail."
    },
    {
      "heading": "Atrial fibrillation ablation",
      "text": "Atrial fibrillation combines abnormal triggering activity with an atrial substrate capable of sustaining disorganized activation. Rapid electrical activity from myocardial sleeves extending into the pulmonary veins is a major source of triggers, particularly in paroxysmal atrial fibrillation. The central ablation strategy is therefore pulmonary vein isolation: creation of electrical block between these sleeves and the left atrium. Contemporary procedures usually place lesions around the venous antra rather than deeply inside the veins, reducing the risk of pulmonary vein narrowing.\n\nRadiofrequency isolation commonly uses a series of contiguous point lesions, while balloon and multielectrode systems create broader lesion patterns. Electrical testing assesses whether activity can enter the veins from the atrium and, when technically assessable, whether activity within the veins can exit into the atrium. The relevant endpoint is electrical isolation, not merely a visually complete ring on a mapping display. Oedema can temporarily conceal gaps, and recovered conduction between the left atrium and pulmonary veins is a frequent finding at repeat procedures.\n\nIn persistent atrial fibrillation, the atrial substrate often includes greater dilation, fibrosis, and conduction heterogeneity. Pulmonary vein isolation remains foundational, but additional targets have included linear lesions, posterior wall isolation, non-pulmonary vein triggers, complex electrograms, and regions of low voltage. These strategies are not interchangeable, and their incremental benefits have varied across trials and populations. Incomplete linear lesions can themselves create channels for organized atrial tachycardia. More extensive ablation therefore does not automatically produce better rhythm control.\n\nClinical outcomes depend on how success is defined. Freedom from any brief recorded recurrence is a stricter endpoint than a substantial reduction in atrial fibrillation burden or improvement in symptoms. Single-procedure success is generally higher in paroxysmal than in persistent disease, and repeat procedures can improve long-term rhythm control. Left atrial size, duration of continuous atrial fibrillation, underlying cardiac disease, and associated conditions such as hypertension, obesity, and obstructive sleep apnoea influence recurrence. These associations do not imply that any one characteristic determines an individual outcome.\n\nAblation and stroke prevention address different clinical problems. Left atrial instrumentation creates a temporary thrombotic hazard, and periprocedural anticoagulation is an important component of procedural care. Longer-term anticoagulation decisions are based principally on underlying stroke risk rather than presumed procedural cure. Silent recurrences and persistent atrial disease help explain this distinction. Early atrial arrhythmias during the post-ablation healing period do not invariably indicate lasting failure, but their timing and burden can carry prognostic information. Ablation also does not directly reverse all structural or vascular conditions associated with atrial fibrillation."
    },
    {
      "heading": "Ventricular tachycardia and premature ventricular complexes",
      "text": "Ventricular arrhythmia ablation encompasses two broad settings: focal arrhythmias in hearts without major structural abnormalities, and arrhythmias associated with myocardial scar or other cardiac disease. The distinction affects mapping, procedural risk, and the meaning of success. A discrete focus producing frequent premature ventricular complexes may be eliminated by a small number of lesions, whereas scar-related ventricular tachycardia can require extensive substrate modification. In either setting, arrhythmia suppression is not equivalent to removal of every underlying cause of sudden cardiac death.\n\nIdiopathic ventricular arrhythmias commonly originate in the ventricular outflow tracts, valve annuli, papillary muscles, or the specialized conduction system. Activation mapping seeks the earliest local ventricular signal preceding the surface QRS complex. Pace mapping provides complementary information, especially when spontaneous ectopy is sparse. Catheter stability can be difficult on moving papillary muscles, and deep intramural or epicardial origins may be inaccessible from a single endocardial surface. Targets near coronary arteries or the normal conduction system introduce additional constraints.\n\nFrequent premature ventricular complexes can, in some patients, cause or aggravate ventricular dysfunction, a condition often termed premature ventricular complex-induced cardiomyopathy. Successful suppression can be followed by improvement in ventricular function. However, the association between ectopic burden and cardiomyopathy is not governed by a universal threshold. Arrhythmia morphology, duration of exposure, underlying myocardial disease, and other factors influence susceptibility. Establishing that ectopy contributes to dysfunction therefore involves more than counting beats on one recording.\n\nAfter myocardial infarction, surviving myocytes within a scar may form channels supporting re-entry. During tolerated ventricular tachycardia, activation and entrainment mapping can identify critical parts of the circuit. Many tachycardias cannot be sustained safely because they cause severe hypotension. In those cases, substrate mapping during sinus rhythm or paced rhythm identifies abnormal electrograms, delayed potentials, and conducting channels for treatment. Non-ischaemic cardiomyopathies may have mid-wall or epicardial scars, making conventional endocardial access less effective.\n\nAn implantable cardioverter-defibrillator terminates dangerous ventricular arrhythmias but does not prevent every recurrence. Ablation is often used to reduce recurrent tachycardia, device therapies, or electrical storm, in which repeated ventricular arrhythmias occur over a short period. It does not automatically replace defibrillator protection. Severe ventricular dysfunction, multiple circuits, difficult substrate access, and haemodynamic instability can make these procedures substantially more complex than most supraventricular ablations. Selected cases involve temporary mechanical circulatory support, epicardial mapping, or specialized approaches to deep myocardial tissue; these add their own risks and are not routine components of every ventricular ablation."
    },
    {
      "heading": "Complications and procedural safety",
      "text": "The risk profile of catheter ablation is determined by vascular access, cardiac chamber, target location, energy source, procedure complexity, and the patient’s underlying condition. A short right-sided supraventricular procedure and an extensive left ventricular scar ablation should not be represented by the same complication estimate. Operator and institutional experience also influence outcomes. Reported rates depend on whether studies count only major events or include minor bleeding, transient conduction changes, and asymptomatic imaging findings.\n\nVascular injury is among the most frequent complications. It includes groin haematoma, bleeding, pseudoaneurysm, arteriovenous fistula, and, less commonly, retroperitoneal haemorrhage. Venous or arterial thrombosis may also occur. Ultrasound-guided access and careful haemostasis are established procedural measures used to reduce access-related problems. Intracardiac catheters can perforate the heart, producing a pericardial effusion or cardiac tamponade. Tamponade impairs cardiac filling and can require urgent drainage or surgical repair.\n\nLeft-sided procedures carry a risk of systemic embolism, including stroke. Potential embolic material includes thrombus, air, and coagulum. Anticoagulation, catheter flushing, and management of sheaths and energy delivery address different components of this risk. Magnetic resonance studies have also detected clinically silent cerebral lesions after some left atrial procedures; their frequency depends on technique and detection methods, and they are not equivalent to symptomatic stroke. Infection, anaesthetic complications, and reactions to medications or contrast agents are additional, generally less frequent hazards.\n\nAnatomical collateral injury varies by target. Ablation near the atrioventricular node can cause complete heart block and a need for permanent pacing. Thermal injury close to a coronary artery may produce coronary damage. Phrenic nerve injury is a recognized complication of procedures near the right-sided pulmonary veins and other adjacent structures. Pulmonary vein stenosis is associated particularly with ablation within the veins. Thermal left atrial ablation can rarely injure the adjacent oesophagus and lead to an atrio-oesophageal fistula, a delayed and potentially fatal complication. The rarity of this event makes very large datasets important for assessing changes in its frequency.\n\nRadiation exposure has fallen with three-dimensional mapping, intracardiac imaging, and low-fluoroscopy workflows, but fluoroscopy remains useful in many laboratories. Energy-specific safeguards do not eliminate non-energy hazards: pulsed-field ablation still requires vascular entry, catheter manipulation, and often transseptal puncture. Structured reporting and patient safety programmes therefore distinguish the mechanism of each adverse event. This separation is essential when comparing devices, since a technology may reduce collateral tissue injury without changing the frequency of access-site bleeding or mechanically caused perforation."
    },
    {
      "heading": "Follow-up, endpoints, and clinical evidence",
      "text": "Follow-up evaluates symptoms, rhythm recurrence, medication use, ventricular function when relevant, and complications. A surface electrocardiogram documents only a short interval, while Holter monitors, patches, implanted devices, and continuous monitors capture different amounts of rhythm information. More intensive monitoring generally detects more asymptomatic recurrence. Consequently, studies using intermittent recordings cannot be compared directly with studies using continuous monitoring unless differences in ascertainment are considered. Symptom improvement alone also cannot establish the complete absence of arrhythmia.\n\nProcedural endpoints and clinical endpoints answer different questions. Acute pulmonary vein isolation or termination of a re-entry circuit shows an immediate electrophysiological effect. Longer-term outcomes include arrhythmia burden, freedom from sustained recurrence, hospitalization, health-related quality of life, and survival. A reduction in short recurrences may not have the same importance as a reduction in disabling episodes or defibrillator shocks. Repeat ablation, continued antiarrhythmic medication, and crossover between treatment groups further complicate interpretation. Studies therefore distinguish single-procedure from multiple-procedure results and outcomes with or without rhythm-control drugs.\n\nThe CABANA randomized controlled trial, reported in 2019, compared catheter ablation with drug therapy in 2,204 patients with atrial fibrillation. Its primary composite endpoint—death, disabling stroke, serious bleeding, or cardiac arrest—did not differ significantly in the primary intention-to-treat analysis. Ablation reduced recurrent atrial fibrillation and improved quality-of-life measures. Substantial crossover from drug therapy to ablation affected interpretation, but analyses based on treatment actually received cannot simply replace the protection against confounding provided by randomization.\n\nThe CASTLE-AF trial, published in 2018, examined a more selected population: patients with atrial fibrillation, symptomatic heart failure, a left ventricular ejection fraction of 35% or less, and an implanted defibrillator. Over a median follow-up of approximately 38 months, death or hospitalization for worsening heart failure occurred in 28.5% of the ablation group and 44.6% of the medical-therapy group. These findings support benefit in an important clinical setting but do not establish an identical survival effect in every patient with atrial fibrillation.\n\nNew technologies are often evaluated against an established ablation method rather than against no treatment. The ADVENT trial, published in 2023, found pulsed-field ablation noninferior to conventional thermal ablation for its prespecified efficacy and safety endpoints in drug-refractory paroxysmal atrial fibrillation. Noninferiority within a defined margin is not proof that two technologies have identical effects, nor can a trial of several hundred patients reliably exclude very rare complications. Registries and longer follow-up complement randomized studies by examining durability, uncommon harms, and performance across a wider range of institutions and patients."
    },
    {
      "heading": "Historical development and technical frontiers",
      "text": "Catheter ablation emerged from diagnostic intracardiac electrophysiology and surgical approaches to arrhythmias. Before reliable catheter methods, some accessory pathways and re-entrant substrates were treated through open cardiac operations. In 1982, clinical reports described catheter delivery of high-energy direct-current shocks to interrupt atrioventricular conduction. These procedures demonstrated that an arrhythmia-related structure could be modified without open-heart surgery, but the shocks were difficult to control and could cause substantial mechanical and electrical injury.\n\nRadiofrequency energy transformed the field in the late 1980s and early 1990s. It allowed more localized, controllable lesions and helped establish accessory pathway and atrioventricular nodal re-entry ablation as practical treatments. Subsequent improvements included steerable catheters, irrigated electrodes, three-dimensional mapping, and better intracardiac imaging. Their effects were complementary: a more effective lesion was useful only when delivered to the correct site, and increasingly accurate mapping required catheters capable of maintaining stable contact.\n\nA major turning point in atrial fibrillation treatment came in 1998, when Michel Haïssaguerre and colleagues reported that ectopic beats originating in the pulmonary veins frequently initiated paroxysmal atrial fibrillation. This observation shifted attention toward pulmonary vein triggers. Early approaches targeted individual foci within the veins; later strategies emphasized electrical isolation, often with wider antral lesion sets. The transition reflected both growing understanding of arrhythmia mechanisms and recognition of complications such as pulmonary vein stenosis.\n\nTechnical development has pursued greater reproducibility as well as new biological mechanisms. Contact-force sensing and integrated lesion indices attempt to standardize point-by-point radiofrequency delivery. Balloon technologies simplify creation of circumferential lesions in suitable anatomy. High-density mapping improves characterization of complex atrial and ventricular circuits. Pulsed-field systems, introduced into wider clinical use in the early 2020s, seek rapid myocardial ablation with reduced injury to selected neighbouring tissues. Each approach still requires evaluation of durable block, clinical outcomes, and device-specific complications.\n\nImportant unresolved technical problems include deeply situated ventricular substrate, distinguishing essential conduction channels from harmless abnormal signals, and predicting which additional lesions improve outcomes beyond pulmonary vein isolation. Bipolar radiofrequency delivery, needle-based ablation, specialized irrigation, and image-integrated targeting have been investigated for tissue beyond the reach of standard catheters. Automated electrogram analysis and machine learning are also being studied as mapping aids. These methods face a central validation problem: an electrically abnormal region is not necessarily indispensable to an arrhythmia, and improved anatomical or signal resolution does not by itself demonstrate improved clinical benefit."
    }
  ],
  "links": [
    "electrophysiology",
    "atrial-fibrillation",
    "fibrosis",
    "cell-membrane",
    "ultrasonography",
    "magnetic-resonance-imaging",
    "x-ray-computed-tomography",
    "anesthesia",
    "fluoroscopy",
    "hypertension",
    "obesity",
    "stroke",
    "thrombosis",
    "embolism",
    "contrast-agent",
    "patient-safety",
    "health-related-quality-of-life",
    "randomized-controlled-trial",
    "intention-to-treat-analysis",
    "machine-learning"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}